Circular Genomics was founded on a breakthrough discovery: the direct link between disease and a new class of brain-enriched circular RNA biomarkers. Today, our proprietary CircPath™ platform transforms that discovery into a powerful engine for interrogating the biology of brain disorders such as Alzheimer’s, Parkinson’s, MS, and others. What makes CircPath™ revolutionary is its ability to capture the full complexity of disease biology and pathology in a single blood draw using brain-enriched circRNAs that cross the blood-brain barrier and reflect real-time central nervous system biology.

Moving beyond today's diagnostic barriers, we are harnessing the power of circular RNA biomarkers, providing researchers, clinicians, and biopharma partners with a real-time view of brain disease via simple blood tests. This means more accurate detection of the disease pathology, leading to potentially faster and more informed treatment selection decisions for several neurological and psychiatric conditions. Our innovation drives a movement toward a future where brain disorders are measurable, manageable, and treatable—empowering patients and families to lead fuller lives, which is the core of our vision.

We are actively advancing a robust pipeline of diagnostic products for Alzheimer’s disease and other neurodegenerative conditions, collaborating with leading partners like Washington University in St. Louis, the Alzheimer’s Drug Discovery Foundation (ADDF), and biotech companies to ensure our solutions remain at the forefront of science and innovation.

Circular Genomics is not just developing tests; we are creating a new standard of care. Advancing brain health requires a deeper, clearer and systems-level view of the molecular mechanisms involved in neurological disorders. By harnessing the unique power of circular RNA biology, we are leading the way to a brighter future in brain health making it —measurable, manageable, and within reach.